{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T11:45:34Z","timestamp":1758282334600,"version":"3.44.0"},"reference-count":5,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T00:00:00Z","timestamp":1758153600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Systemic light chain amyloidosis (AL) is an uncommon disorder of clonal plasma cells, marked by the creation of amyloid-forming immunoglobulin light chains that result in amyloid fibril formation and deposition, causing dysfunction in multiple organs. There is no established treatment protocol for patients with relapsed or refractory AL. Teclistamab is a bispecific antibody targeting B-cell maturation antigen (BCMA) and is approved for treating relapsed or refractory multiple myeloma (MM). The objective of our study was to report real-world data on the safety and efficacy of teclistamab in patients with relapsed\/refractory AL.<\/jats:p>","DOI":"10.3389\/fonc.2025.1664171","type":"journal-article","created":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T04:12:31Z","timestamp":1758168751000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case Report: Safety and efficacy assessment of teclistamab in relapsed\/refractory amyloidosis: a case study"],"prefix":"10.3389","volume":"15","author":[{"given":"Zhe","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhijian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jieni","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leihua","family":"Fu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiaping","family":"Fu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiying","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1001\/jama.2020.5493","article-title":"Systemic amyloidosis recognition, prognosis, and therapy: A systematic review","volume":"324","author":"Gertz","year":"2020","journal-title":"Jama"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-11-751628","article-title":"Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death","volume":"129","author":"Muchtar","year":"2017","journal-title":"Blood"},{"key":"B3","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1038\/s41408-022-00717-2","article-title":"High response rates with single-agent belantamab mafodotin in relapsed systemic AL amyloidosis","volume":"12","author":"Khwaja","year":"2022","journal-title":"Blood Cancer J"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023022937","article-title":"Teclistamab in relapsed or refractory AL amyloidosis: a multinational retrospective case series","volume":"143","author":"Forgeard","year":"2024","journal-title":"Blood"},{"key":"B5","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N Engl J Med"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1664171\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T04:12:41Z","timestamp":1758168761000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1664171\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,18]]},"references-count":5,"alternative-id":["10.3389\/fonc.2025.1664171"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1664171","relation":{},"ISSN":["2234-943X"],"issn-type":[{"type":"electronic","value":"2234-943X"}],"subject":[],"published":{"date-parts":[[2025,9,18]]},"article-number":"1664171"}}